Sellas Life Sciences (NASDAQ:SLS) experienced a 13.15% drop in share price, closing at $13.21, amid growing investor concerns regarding the company’s treatment candidate for acute myeloid leukemia, Galinpepimut-S (GPS). This decline followed reports indicating the company reached an important milestone in its clinical trial, with the 80th patient death occurring, but remained silent about it. Additionally, Sellas reported a widening net loss of $9.6 million for Q2, a 45.5% increase from the previous year, and hinted at a potential takeover through amended employment agreements for key executives. Despite these challenges, institutional investors showed increased commitment to the company, boosting their holdings significantly.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://finance.yahoo.com/markets/stocks/articles/sellas-life-sls-falls-13-031651183.html
